Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Ending Cash Position: ₹-51 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MADHAVBAUG Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
73 GF Score
Price ₹159.35
GF Value ₹228.31
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Vaidyane Ayurved Laboratories Ending Cash Position?

Vaidyane Ayurved Laboratories NSE:MADHAVBAUG +0.25% 73 Ending Cash Position is ₹-51 Mil as of Mar. 2026. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 73/100 and a GF Value™ of ₹228.31 (Possible Value Trap). The stock has 4 warning signs investors should review.

Vaidyane Ayurved Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 was ₹-51 Mil.

Vaidyane Ayurved Laboratories's quarterly Ending Cash Position increased from Mar. 2025 (₹2 Mil) to Sep. 2025 (₹55 Mil) but then declined from Sep. 2025 (₹55 Mil) to Mar. 2026 (₹-51 Mil).

Vaidyane Ayurved Laboratories's annual Ending Cash Position declined from Mar. 2024 (₹24 Mil) to Mar. 2025 (₹24 Mil) and declined from Mar. 2025 (₹24 Mil) to Mar. 2026 (₹4 Mil).

Vaidyane Ayurved Laboratories Ending Cash Position Related Terms

Vaidyane Ayurved Laboratories Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vaidyane Ayurved Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaidyane Ayurved Laboratories Ending Cash Position Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial 25.61 17.64 23.73 23.60 4.37

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.73 21.76 1.84 55.38 -51.01
NSE:MADHAVBAUG
73GF Score
Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaidyane Ayurved Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vaidyane Ayurved Laboratories's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.6+-19.228
=4

Vaidyane Ayurved Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-0.00099999999999056+-51.01
=-51

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹-51 Mil mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Ending Cash Position of ₹-51 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vaidyane Ayurved Laboratories and its competitors.
Is Vaidyane Ayurved Laboratories' Ending Cash Position too high?
Vaidyane Ayurved Laboratories' current Ending Cash Position is ₹-51 Mil. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Ending Cash Position compare to ZTS?
Vaidyane Ayurved Laboratories' Ending Cash Position of ₹-51 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vaidyane Ayurved Laboratories and its competitors. Vaidyane Ayurved Laboratories's current Ending Cash Position is ₹-51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Possible Value Trap. The stock's GF Value™ is ₹228.31, compared to a current price of ₹159.35 — trading 30.2% below its estimated fair value. The current Ending Cash Position is ₹-51 Mil. Vaidyane Ayurved Laboratories' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Ending Cash Position is ₹-51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?

Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued. The current stock price of ₹159.35 is trading 30.2% below its estimated GF Value™ of ₹228.31. GuruFocus considers Vaidyane Ayurved Laboratories to be Possible Value Trap.

Key valuation signals for NSE:MADHAVBAUG:

  • Ending Cash Position: ₹-51 Mil
  • GF Value™: ₹228.31 vs. price of ₹159.35 (30.2% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaidyane Ayurved Laboratories Business Description

Address 201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
73GF Score

Get the complete analysis for NSE:MADHAVBAUG

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹159.35
Price
₹228.31
GF Value